Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2006

01-10-2006 | Case Reports

A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy

Authors: Sonia Maciá Escalante, Álvaro Rodríguez Lescure, Vanesa Pons Sanz, Natividad Martínez Banaclocha, Carmen Guillén Ponce, Alfredo Carrato Mena

Published in: Clinical and Translational Oncology | Issue 10/2006

Login to get access
Metadata
Title
A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy
Authors
Sonia Maciá Escalante
Álvaro Rodríguez Lescure
Vanesa Pons Sanz
Natividad Martínez Banaclocha
Carmen Guillén Ponce
Alfredo Carrato Mena
Publication date
01-10-2006
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 10/2006
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-006-0125-6

Other articles of this Issue 10/2006

Clinical and Translational Oncology 10/2006 Go to the issue

Case reports

Papillary serous carcinoma of peritoneum: presentation of 2 cases

Case Reports

Controversial origin ofPseudomyxoma peritonei

News and Views

The «other» medicine

Educational Series

Tumor metabolism: new opportunities for cancer therapy

Brief Research Articles

Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

Editorial

Advances in neuroblastoma research
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits